Sulfur hexafluoride
As of the edition of 20 October 2026, Sulfur hexafluoride is a small molecule: marketed, first approved in 2001 (EU).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Lumason
- First approved
- 26 March 2001 (EU)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Bracco Diagnostics; 3 holders in all
- Registered trials
- 68, 16 stopped early
- Disease areas
- Cancer; Digestive system; Heart and blood vessels; Urinary and reproductive; Nervous system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 7 | 3 | 2 |
| Phase 1 | 13 | 4 | 5 | 4 |
| Phase 2 | 16 | 9 | 4 | 2 |
| Phase 3 | 17 | 7 | 5 | 4 |
| Phase 4 | 9 | 3 | 2 | 4 |
| All trials | 68 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bracco | Applicant | 2001 to now |
| Bracco Imaging | Applicant | 2006 to now |
| Bracco Diagnostics | Applicant and Lead sponsor of trials | 2010 to now |